Moderna shares rose nearly 20% after Science Day, driven partly by a short squeeze, while its mRNA pipeline beyond vaccines ...
Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and ...
Introducing Claude Science, the AI platform designed to expedite the discovery of promising new therapies. Anthropic will ...
Morning Overview on MSN
A Moderna mRNA flu shot won a unanimous FDA panel nod for older adults
Older adults who face the highest rates of flu hospitalization moved one step closer to a new vaccine option on June 18, 2026 ...
The health agency is conducting a trial on the first potentially effective treatments for Bundibugyo virus, while adding the first diagnostic test to its emergency use list.
The mRNA vaccines approved to treat COVID-19 are safe and effective and show promise in treating other diseases including ...
B.C.’s globally competitive biotech sector is pushing forward with more UBC-spin-off companies that harness both research and ...
Anthropic's Claude Science is a workbench that gives scientists one environment to do computational research, saving them ...
Wall Street’s best trade this month wasn’t owning a hot stock. It was betting against one — and not just any stocks, but ...
A new food hall with Michelin cred has arrived on a biotech campus in South San Francisco - and you don't have to be an ...
A comprehensive new review published in The Lancet affirms that currently approved mRNA vaccines are safe and highly ...
Adults who received the updated mRNA-1273 COVID-19 vaccine experienced a lower risk for hospitalization compared with NVX-CoV2705 recipients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results